Schulz R - Search Results

1

HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates.

Schulz R, Dobbelstein M, Moll UM. Schulz R, et al. Oncoimmunology. 2012 Nov 1;1(8):1425-1426. doi: 10.4161/onci.21173. Oncoimmunology. 2012. PMID: 23243616 Free PMC article.

2

HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.

Schulz R, Streller F, Scheel AH, Rüschoff J, Reinert MC, Dobbelstein M, Marchenko ND, Moll UM. Schulz R, et al. Cell Death Dis. 2014 Jan 2;5(1):e980. doi: 10.1038/cddis.2013.508. Cell Death Dis. 2014. PMID: 24384723 Free PMC article.

3

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.

Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM. Alexandrova EM, et al. Among authors: schulz r. Nature. 2015 Jul 16;523(7560):352-6. doi: 10.1038/nature14430. Epub 2015 May 25. Nature. 2015. PMID: 26009011 Free PMC article.

4

While p73 is essential, p63 is completely dispensable for the development of the central nervous system.

Holembowski L, Schulz R, Talos F, Scheel A, Wolff S, Dobbelstein M, Moll U. Holembowski L, et al. Among authors: schulz r. Cell Cycle. 2011 Feb 15;10(4):680-9. doi: 10.4161/cc.10.4.14859. Epub 2011 Feb 15. Cell Cycle. 2011. PMID: 21293190 Free PMC article.

5

Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.

Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L, Dobbelstein M, Moll UM. Schulz R, et al. J Exp Med. 2012 Feb 13;209(2):275-89. doi: 10.1084/jem.20111117. Epub 2012 Jan 23. J Exp Med. 2012. PMID: 22271573 Free PMC article.

6

Targeting the heat shock protein 90: a rational way to inhibit macrophage migration inhibitory factor function in cancer.

Schulz R, Moll UM. Schulz R, et al. Curr Opin Oncol. 2014 Jan;26(1):108-13. doi: 10.1097/CCO.0000000000000036. Curr Opin Oncol. 2014. PMID: 24225413 Review.

7

MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.

Zhang X, Schulz R, Edmunds S, Krüger E, Markert E, Gaedcke J, Cormet-Boyaka E, Ghadimi M, Beissbarth T, Levine AJ, Moll UM, Dobbelstein M. Zhang X, et al. Among authors: schulz r. Mol Cell. 2015 Jul 16;59(2):243-57. doi: 10.1016/j.molcel.2015.05.036. Epub 2015 Jul 2. Mol Cell. 2015. PMID: 26145175 Free article.

8

Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.

Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, Moll UM. Li D, et al. Among authors: schulz r. Mol Cancer Res. 2011 May;9(5):577-88. doi: 10.1158/1541-7786.MCR-10-0534. Epub 2011 Apr 8. Mol Cancer Res. 2011. PMID: 21478269 Free PMC article.

9

p63 and canonical Wnt signaling.

Talos F, Schulz R, Moll UM. Talos F, et al. Among authors: schulz r. Cell Cycle. 2010 Feb 15;9(4):648-9. Epub 2010 Feb 15. Cell Cycle. 2010. PMID: 20190579 No abstract available.

10

Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.

Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM. Alexandrova EM, et al. Among authors: schulz r. Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15720. Epub 2015 Sep 30. Nature. 2015. PMID: 26416737 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,624 results

Search Page

Filters